<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="31980">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02690337</url>
  </required_header>
  <id_info>
    <org_study_id>DS1123-A-J101</org_study_id>
    <nct_id>NCT02690337</nct_id>
  </id_info>
  <brief_title>Study of DS-1123a in Advanced Solid Tumours</brief_title>
  <official_title>Phase 1, Open-label Study to Assess the Safety, Tolerability, and Pharmacokinetics of DS-1123a in Subjects With Advanced Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Daiichi Sankyo Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Daiichi Sankyo Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label study to evaluate the safety, tolerability, and pharmacokinetics of
      DS-1123a in Japanese subjects with advanced solid tumors.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2016</start_date>
  <completion_date type="Anticipated">April 2017</completion_date>
  <primary_completion_date type="Anticipated">February 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>maximum concentration Cmax</measure>
    <time_frame>Cycles 1, 2 : Days 1,2, 4, 8, 15</time_frame>
    <description>pharmacokinetics profile</description>
  </primary_outcome>
  <primary_outcome>
    <measure>number and severity of treatment emergent adverse events (TEAEs)</measure>
    <time_frame>Day 1 to Day 31</time_frame>
    <description>number and severity of treatment emergent adverse events (TEAEs)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>time of maximum concentration Tmax</measure>
    <time_frame>Cycles 1, 2: Days 1,2, 4, 8, 15</time_frame>
    <description>pharmacokinetics profile:</description>
  </primary_outcome>
  <primary_outcome>
    <measure>elimination rate constant Kel</measure>
    <time_frame>Cycles 1, 2: Days 1,2, 4, 8, 15</time_frame>
    <description>pharmacokinetics profile</description>
  </primary_outcome>
  <primary_outcome>
    <measure>area under the curve AUClast</measure>
    <time_frame>Cycles 1, 2: Days 1,2, 4, 8, 15</time_frame>
    <description>pharmacokinetics profile</description>
  </primary_outcome>
  <primary_outcome>
    <measure>area under the curve AUCtau</measure>
    <time_frame>Cycles 1, 2: Days 1,2, 4, 8, 15</time_frame>
    <description>pharmacokinetics profile</description>
  </primary_outcome>
  <primary_outcome>
    <measure>area under the curve AUCinf</measure>
    <time_frame>Cycles 1, 2: Days 1,2, 4, 8, 15</time_frame>
    <description>pharmacokinetics profile</description>
  </primary_outcome>
  <primary_outcome>
    <measure>half-life T1/2</measure>
    <time_frame>Cycles 1, 2: Days 1,2, 4, 8, 15</time_frame>
    <description>pharmacokinetics profile</description>
  </primary_outcome>
  <primary_outcome>
    <measure>drug clearance CL</measure>
    <time_frame>Cycles 1, 2: Days 1,2, 4, 8, 15</time_frame>
    <description>pharmacokinetics profile</description>
  </primary_outcome>
  <primary_outcome>
    <measure>volume of distribution Vz</measure>
    <time_frame>Cycles 1, 2: Days 1,2, 4, 8, 15</time_frame>
    <description>pharmacokinetics profile</description>
  </primary_outcome>
  <primary_outcome>
    <measure>mean residence time MRTinf</measure>
    <time_frame>Cycles 1, 2: Days 1,2, 4, 8, 15</time_frame>
    <description>pharmacokinetics profile</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>DS-1123a antibody</measure>
    <time_frame>Cycle 1: Days 1,15; Cycles 2: Day 1; Stop date, final follow-up date</time_frame>
    <description>DS-1123a antibody on Cycle 1: Days 1,15; Cycles 2 and on: Day 1, Stop date, final follow-up date</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Cytokines expression</measure>
    <time_frame>Cycle 1: Days 1, 2, 15, 16; Cycle 2: Days 1, 2</time_frame>
    <description>Change in DS-1123a biomarkers Cytokines expression on Cycle 1: Days 1, 2, 15, 16; Cycle 2: Days 1, 2</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">18</enrollment>
  <condition>Advanced Solid Malignant Tumors</condition>
  <arm_group>
    <arm_group_label>DS-1123</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This study will follow a modified Continual Reassessment Method (mCRM) + Escalation with Overdose Control (EWOC),design with a starting intravenous (IV) dose of 0.1 mg/kg.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DS-1123</intervention_name>
    <description>starting intravenous (IV) dose of 0.1 mg/kg.</description>
    <arm_group_label>DS-1123</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Advanced solid tumor that is refractory to standard treatment, or for which no
             standard treatment is available.

          -  Eastern Cooperative Oncology Group performance status (PS) of 0 or 1.

        Exclusion Criteria:

          -  Have any of the following concomitant disease or had the history of having following
             disease within 6 months before enrollment:

             • Cardiac failure (NYHA ≥ ClassIII), myocardial infarction, cerebral infarction,
             unstable angina, arrhythmia requiring treatment, coronary-artery/peripheral artery
             bypass surgery, cerebrovascular disease, pulmonary thromboembolism, deep-vein
             thrombosis or clinically severe thromboembolic event, or clinically severe pulmonary
             disease (eg, interstitial pneumonia, pulmonary fibrosis, radiation pneumonia, drug
             induced pneumonia),

          -  Severe or uncontrolled concomitant disease.

          -  Clinically active brain metastases defined as symptomatic or requiring treatment.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Satoru Iwasa, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Cancer Center Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Marie Shiga, Ast. Mgr.</last_name>
    <phone>81-3-3492-3131</phone>
  </overall_contact>
  <location>
    <facility>
      <address>
        <city>Tokyo</city>
        <zip>277-8577</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>August 2016</verification_date>
  <lastchanged_date>August 22, 2016</lastchanged_date>
  <firstreceived_date>February 4, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Advanced solid malignant tumors</keyword>
  <keyword>phase 1</keyword>
  <keyword>oncology</keyword>
  <keyword>refractory</keyword>
  <keyword>no standard treatment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
